09:42 AM EST - BioVaxys Technology Corp. : Announced today that it is expanding its intellectual property portfolio with the filing of an international patent application through the Patent Cooperation Treaty ("PCT") for its haptenized viral antigen vaccine platform, including new claims for a multivalent version of BVX-0320, its SARS-CoV-2 vaccine candidate. The planned multivalent version of the BioVaxys vaccine is a combination of the haptenized spike protein subunits from each newly emerging, highly transmissible, SARS-CoV-2 variants, including United Kingdom (B.1.1.7 lineage), South Africa (B.1.351 lineage), and Brazil (P.1 lineage), that are of high concern to worldwide governments, healthcare practitioners, and infectious disease researchers. BioVaxys Technology Corp.
shares C.BIOV are trading up 1 cent at $0.42.